肾动脉内注射L-精氨酸抑制肾神经传入纤维的自发活动

研究旨在应用记录肾传人神经多单位和单位放电的方法,观察肾动脉内注射L—精氨酸对麻醉家兔肾神经传人纤维自发放电活动的影响。结果表明：(1）肾动脉内注射L—精氨酸(0．05、0．24和0．48mmol/kg)可呈剂量依赖性地抑制肾传人纤维的活动,而动脉血压不变;(2)静脉内预先注射一氧化氮合酶抑制剂L—NAME(0．11mmol/kg),可完全阻断L—精氨酸对肾传人纤维的抑制;(3)肾动脉注射一氧化氮(N0)供体SIN—1(3．75μmol/kg)也可抑制肾传入神经的活动。以上结果提示：肾动脉内应用N0前体L—精氨酸和N0供体SIN—1均可抑制肾传入纤维的自发活动。     

肾动脉内注射腺苷兴奋肾神经传入纤维的自发活动

应用记录肾神经传入纤维多单位和单位放电的方法,观察肾动脉内注射腺苷对麻醉家兔肾神经传入纤维自发放电活动的影响。结果表明：(1)肾动脉内注射50,100和200nmol／kg腺苷可呈剂量依赖性地兴奋肾神经传入纤维的活动,而动脉血压不变。(2)肾动脉内预先应用选择性腺苷A1受体阻断剂DPCPX(160nmol/kg),可部分阻断腺苷对肾神经传入纤维的兴奋作用。(3)静脉应用一氧化氮合酶抑制剂L-NAME(0．1mmol／kg)预处理,延长并增强了肾神经传入纤维对腺苷的反应。以上结果提示,肾动脉内应用腺苷可兴奋肾传入纤维的自发放电活动,一氧化氮作为抑制性因素参与腺苷诱导的肾神经传入纤维兴奋。     

HER

在48只麻醉家兔, 应用记录肾传入神经多单位和单位放电方法, 观察了肾动脉内注射缓激肽(bradykinin, BK, 5.0 g/kg)对肾传入神经活动(ARNA) 的影响。 结果表明 (1)肾动脉内应用BK引起ARNA双相激活。 ARNA 激活的初发相在肾动脉注射 BK 后迅速出现, 延迟相则见于注射后7 min左右, 且延迟相的激活作用大于初发相。 (2)静脉内预先注射前列环素合成阻断剂Indomethacin (Indo, 5.0mg/kg), 可部分阻断BK引起的ARNA延迟相的激活, 对初发相的激活并无影响; (3)静脉内预先注射NO合酶抑制剂 L-NAME (30.0 mg/kg), 可完全阻断BK引起的ARNA延迟相的激活, 而对初发相仅有部分阻断作用。 本实验提示 肾内应用缓激肽所致ARNA初发相的激活, 可归因于BK的直接作用及其所诱发NO的释放, 延迟相的激活主要在于BK引起前列环素和NO释放的结果。     

肾动脉内注射缓激肽对麻醉家兔肾传入神经放电的双相激活

在48只麻醉家兔,应用记录肾传入神经多单位和单位放电方法,观察了肾动脉内注射缓激肽(bradykinin,BK,50g/kg)对肾传入神经活动(ARNA)的影响。结果表明:(1)肾动脉内应用BK引起ARNA双相激活。ARNA激活的初发相在肾动脉注射BK后迅速出现,延迟相则见于注射后7min左右,且延迟相的激活作用大于初发相。(2)静脉内预先注射前列环素合成阻断剂Indomethacin(Indo,50mg/kg),可部分阻断BK引起的ARNA延迟相的激活,对初发相的激活并无影响;(3)静脉内预先注射NO合酶抑制剂LNAME(300mg/kg),可完全阻断BK引起的ARNA延迟相的激活,而对初发相仅有部分阻断作用。本实验提示:肾内应用缓激肽所致ARNA初发相的激活,可归因于BK的直接作用及其所诱发NO的释放,延迟相的激活主要在于BK引起前列环素和NO释放的结果。     

刺激家兔肾内感受器的传入神经活动观察

在44只麻醉家兔观察肾机械和化学感受器刺激对肾传入神经放电活动的影响。结果如下:(1)输尿管压增高20.20±1.09mmHg 引起肾传入神经放电的积分值增加175.13±22.41,(P<0.001)。(2)经输尿管向肾盂内逆向灌注0.15mol/L KCl 和 1mol/L NaCl 溶液时,肾传入神经放电积分值分别增加253.79±21.64%和172.17±15.19%(P<0.001)。(3)肾传入神经纤维的单位放电至少有四种类型:无自发放电活动,自发规则放电,自发规则的猝发放电和不规则放电。(4)输尿管压增高可诱发无自发活动的肾传入神经出现明显的放电,而有自发放电的单位对此种刺激不敏感。(5)向肾盂内逆向灌流0.15mol/L KCl 和1mol/L NaCl 溶液时,肾传入神经自发放电单位的电活动分别增加210.70±23.40%,6和140.07±15.72%(P<0.001),并有新的单位被激活。(6)夹闭肾动脉可诱发无自发活动的肾传入神经单位的放电活动。以上结果提示,家兔肾脏内存在机械和 R_1, R_2化学感受器,分别感受输尿管压、肾缺血和肾盂浸浴液中 Na~+,K~+浓度的变化。     

最后区微量注射辣椒素对大鼠血压、心率和肾交感神经放电的影响

在36只麻醉Sprague-Dawley大鼠, 观察了最后区内微量注射辣椒素(10 μmol/L, 50 nl)对平均动脉压(MAP)、心率(HR)和肾交感神经放电(RSNA)的影响.实验结果如下:(1)最后区内注射辣椒素可引起 MAP、HR 和RSNA明显增加, 分别由12.34±0.53 kPa、 328.52±7.54 bpm 和100±0% 增至15.17±0.25 kPa (P<0.001)、 354.81±8.54 bpm (P<0.001) 和156.95±7.57% (P<0.001);(2) 静脉注射辣椒素受体阻断剂钌红(100 mmol/L, 0.2 ml) 后, 辣椒素的上述效应可被明显抑制;(3) 预先应用NMDA 受体阻断剂MK-801 (500 μg/kg, 0.2 ml, iv)也明显抑制辣椒素的兴奋效应.以上结果提示, 最后区微量注射辣椒素对血压、心率和肾交感神经放电有兴奋作用, 而此作用由辣椒素受体介导并有谷氨酸参与.     

缓激肽加强辣椒素引起的关节传入神经细纤维的反应

利用猫膝关节传入神经单纤维记录技术,观察了正常和炎症关节传入Ⅲ、Ⅳ类纤维对缓激肽(BK)的反应以及BK对辣椒素(CAP)反应的影响。在29只猫上共计记录了51条单纤维。其中正常关节22条,炎症关节29条。与正常关节传入纤维比较,炎症关节纤维中有自发放电的单位比例明显增多,且放电频率较高,被动运动分型以低机械阈值的纤维居多,CAP兴奋的阈值也较正常为低。部分纤维在使用BK后,自发放电明显增加。无论在正常还是炎症关节,被BK兴奋的单纤维中约有1/3不被CAP兴奋,而CAP兴奋的纤维则几乎全部可为BK激活,BK兴奋伤害性传入纤维的选择性不如CAP。结果提示:(1)BK可以使关节传入纤维致敏,使其对化学刺激剂CAP反应增强,并可使部分对CAP无反应的单位出现对CAP的反应;(2)炎症造成的致敏背景是外源性炎症介质易化感受器反应的重要条件;(3)对BK的反应性是纤维被BK致敏的一个条件。     

辣椒素对大鼠延髓腹外侧头端区神经元电活动的影响

在35只切断两侧缓冲神经的麻醉大鼠,应用细胞外记录的电生理学方法,观察颈总动脉注射辣椒素(capsaicin)对延髓腹外侧头端区(RVLM)巨细胞旁外侧核(PGL)自发电活动的影响。所得结果如下:(1)颈动脉注射辣椒素(10μmol,01ml),MAP由1074±013升至1256±021kPa(P<0001);HR由374±4增至395±5bpm(P<0001);30个PGL神经元自发放电单位的放电频率由126±07增至209±11spikes/s(P<0001)。(2)在10个放电单位,应用辣椒素受体阻断剂钌红(rutheniumred;200mmol,01ml)后,明显抑制辣椒素的上述效应。以上结果提示,辣椒素可能通过激活RVLM神经元上的辣椒素受体,进而兴奋PGL神经元     

颈动脉注射肾上腺髓质素对去缓冲神经大鼠最后区神经元自发放电的影响

在63只切断两侧缓冲神经的麻醉sprague-Dawley大鼠,应用细胞外记录的电生理学方法,观察颈内动脉注射肾上腺髓质素(adrenomedullin,AM)对最后区(area postrema,AP)神经元自发电活动的影响。实验结果如下:(1)在记录到的78个自发放电单位中,颈内动脉内注射AM(0.3 nmol/kg),引起其中47个单位的自发放电频率由2.99±0.24增加到4.79±0.29 spikes/s(P<0.001),20个单位自发放电频率由3.24±0.46下降至1.97±0.37 spikes/s(P<0.001),另外11个单位自发放电频率无明显改变;平均动脉压和心率无明显变化。(2)颈内动脉注射降钙素基因相关肽受体阻断剂CGRP_(8-37)(3 nmol/kg)不能改变AM对自发放电的兴奋效应;(3)颈内动脉注射L-精氨酸(30 mg/kg)可减弱AM对自发放电的兴奋效应。以上结果提示,AM对最后区神经元有兴奋作用,此作用不是由降钙素基因相关肽受体介导,但可被NO前体L-精氨酸所减弱。     

颈动脉注射17β -雌二醇对去缓冲神经大鼠延髓腹外侧头端区神经元放电活动的影响

本研究旨在观察17β-雌二醇(E2)对雄性大鼠延髓腹外侧头端区(RVLM)神经元自发放电活动的影响.在切断双侧缓冲神经的麻醉雄性Sprague-Dawley大鼠上,同步记录血压、心率和RVLM神经元的自发放电活动.颈动脉内注射E2 (10 ng/kg),30个RVLM神经元自发放电单位中有25个单位的放电频率由14.46±0.47降至9.73±0.33 spikes/s (P<0.05),与此同时血压和心率无明显改变.E2的抑制效应在1 min内起效,持续时间长于5 min.雌激素受体拮抗剂tamoxifen (5 mg/kg)不能阻断E2 的抑制效应.预先给予一氧化氮(NO)合酶阻断剂L-NAME (2.7 μg/kg)能明显阻断E2的抑制效应.应用NO供体SIN-1 (0.5 μg/kg)可增强E2的抑制效应.以上结果提示,E2可通过非基因组效应激活RVLM神经元的NOS而引发NO释放,进而抑制其自发放电活动.     

肾动脉内注射缓激肽对麻醉家兔肾伟入神经放电的双相激活

The effect of intrarenal artery injection of bradykinin (BK, 5.0 micrograms/kg) on multi- and single-unit recordings of afferent renal nerve activity (ARNA) was examined in anesthetized 48 rabbits. The results obtained are as follows. (1) There were two phases of increase in ARNA following intrarenal BK. The early phase occurred immediately while the delayed phase made its appearance about 7 min later. The degree of increase in ARNA of the delayed phase induced by intrarenal BK was more prominent than that in the early phase. BP was actually unaltered following intrarenal BK. (2) By pretreatment with indomethacin (Indo, 5.0 mg/kg), the delayed phase of increase in ARNA induced by intrarenal BK was attenuated, while the early phase was not affected. (3) Pretreatment with L-NAME (30 mg/kg) led the delayed phase to be blocked completely while the early phase was partially decreased. From the above-mentioned observations, it is concluded that intrarenal BK induces a significant increase in ARNA in two phases. The early phase may be due to the direct action of BK and partially due to the NO action, while the delayed phase may be attributed to the action of released prostaglandin and NO as a result of intrarenal BK.     

Nitric oxide modulates renal sensory nerve fibers by mechanisms related to substance P receptor activation

Nerve terminals containing neuronal nitric oxide synthase (nNOS) are localized in the renal pelvic wall where the sensory nerves containing substance P and calcitonin gene-related peptide (CGRP) are found. We examined whether nNOS is colocalized with substance P and CGRP. All renal pelvic nerve fibers that contained nNOS-like immunoreactivity (-LI) also contained substance P-LI and CGRP-LI. In anesthetized rats, renal pelvic perfusion with the nNOS inhibitor S-methyl-L-thiocitrulline (L-SMTC, 20 microM) prolonged the afferent renal nerve activity (ARNA) response to a 3-min period of increased renal pelvic pressure from 5 +/- 0.4 to 21 +/- 2 min (P < 0.01, n = 14). The magnitude of the ARNA response was unaffected by L-SMTC. Similar effects were produced by N(omega)-nitro-L-arginine methyl ester (L-NAME) but not D-NAME. Increasing renal pelvic pressure produced similar increases in renal pelvic release of substance P before and during L-SMTC, from 5.9 +/- 1.4 to 13.6 +/- 4.2 pg/min before and from 4.9 +/- to 12.6 +/- 2.7 pg/min during L-SMTC. L-SMTC also prolonged the ARNA response to renal pelvic perfusion with substance P (3 microM) from 1.2 +/- 0.2 to 5.6 +/- 1.1 min (P < 0.01, n = 9) without affecting the magnitude of the ARNA response. In conclusion: activation of NO may function as an inhibitory neurotransmitter regulating the activation of renal mechanosensory nerve fibers by mechanisms related to activation of substance P receptors.     

Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers

Increasing efferent renal sympathetic nerve activity (ERSNA) increases afferent renal nerve activity (ARNA). To test whether the ERSNA-induced increases in ARNA involved norepinephrine activating alpha-adrenoceptors on the renal sensory nerves, we examined the effects of renal pelvic administration of the alpha(1)- and alpha(2)-adrenoceptor antagonists prazosin and rauwolscine on the ARNA responses to reflex increases in ERSNA (placing the rat's tail in 49 degrees C water) and renal pelvic perfusion with norepinephrine in anesthetized rats. Hot tail increased ERSNA and ARNA, 6,930 +/- 900 and 4,870 +/- 670%.s (area under the curve ARNA vs. time). Renal pelvic perfusion with norepinephrine increased ARNA 1,870 +/- 210%.s. Immunohistochemical studies showed that the sympathetic and sensory nerves were closely related in the pelvic wall. Renal pelvic perfusion with prazosin blocked and rauwolscine enhanced the ARNA responses to reflex increases in ERSNA and norepinephrine. Studies in a denervated renal pelvic wall preparation showed that norepinephrine increased substance P release, from 8 +/- 1 to 16 +/- 1 pg/min, and PGE(2) release, from 77 +/- 11 to 161 +/- 23 pg/min, suggesting a role for PGE(2) in the norepinephrine-induced activation of renal sensory nerves. Prazosin and indomethacin reduced and rauwolscine enhanced the norepinephrine-induced increases in substance P and PGE(2). PGE(2) enhanced the norepinephrine-induced activation of renal sensory nerves by stimulation of EP4 receptors. Interaction between ERSNA and ARNA is modulated by norepinephrine, which increases and decreases the activation of the renal sensory nerves by stimulating alpha(1)- and alpha(2)-adrenoceptors, respectively, on the renal pelvic sensory nerve fibers. Norepinephrine-induced activation of the sensory nerves is dependent on renal pelvic synthesis/release of PGE(2).     

NO和ANP对内皮素引起大鼠肾神经传入放电增加的阻抑作用

目的和方法：采用电生理学技术观察一氧化氮（NO）和心房钠尿肽（ANP）对肾动脉内注射内皮素（ET）所致麻醉大鼠肾神经传入放电（RANA）的影响。结果：①肾动脉内注射ET－1后平均动脉压（MAP）先有短暂的降低随后为较显著的持久增高,RANA明显增加;②肾动脉内分别注射NO前体L－Arg和ANP后,ET－1的上述效应即被阻抑。结论：肾动脉ET－1引起RANA明显增加,百此效应可被同一途径注射NO和ANP所消除。     

PGE(2) increases release of substance P from renal sensory nerves by activating the cAMP-PKA transduction cascade

Increasing renal pelvic pressure increases afferent renal nerve activity (ARNA) by a PGE(2)-mediated release of substance P (SP) from renal pelvic nerves. The role of cAMP activation in the PGE(2)-mediated release of SP was studied by examining the effects of the adenylyl cyclase (AC) activator forskolin and AC inhibitor dideoxyadenosine (DDA). Forskolin enhanced the bradykinin-mediated release of SP from an isolated rat renal pelvic wall preparation, from 7.3 +/- 1.3 to 15.6 +/- 3.0 pg/min. PGE(2) at a subthreshold concentration for SP release mimicked the effects of forskolin. The EP(2) receptor agonist butaprost, 15 microM, and PGE(2), 0.14 microM, produced similar increases in SP release, from 5.8 +/- 0.8 to 17.0 +/- 2.3 pg/min and from 8.0 +/- 1.3 to 21.6 +/- 2.7 pg/min. DDA blocked the SP release produced by butaprost and PGE(2). The PGE(2)-induced release of SP was also blocked by the PKA inhibitors PKI(14-22) and H-89. Studies in anesthetized rats showed that renal pelvic administration of butaprost, 10 microM, and PGE(2), 0.14 microM, resulted in similar ARNA responses, 1,520 +/- 390 and 1,170 +/- 270%. s (area under the curve of ARNA vs. time) that were blocked by DDA. Likewise, the ARNA response to increased renal pelvic pressure, 7,180 +/- 710%. s, was blocked by DDA. In conclusion, PGE(2) activates the cAMP-PKA pathway leading to a release of SP and activation of renal pelvic mechanosensory nerve fibers.     

Activation of renal mechanosensitive neurons involves bradykinin, protein kinase C, PGE(2), and substance P

Increased renal pelvic pressure or bradykinin increases afferent renal nerve activity (ARNA) via PGE(2)-induced release of substance P. Protein kinase C (PKC) activation increases ARNA, and PKC inhibition blocks the ARNA response to bradykinin. We now examined whether bradykinin mediates the ARNA response to increased renal pelvic pressure by activating PKC. In anesthetized rats, the ARNA responses to increased renal pelvic pressure were blocked by renal pelvic perfusion with the bradykinin B(2)-receptor antagonist HOE 140 and the PKC inhibitor calphostin C by 76 +/- 8% (P < 0.02) and 81 +/- 5% (P < 0.01), respectively. Renal pelvic perfusion with 4beta-phorbol 12,13-dibutyrate (PDBu) to activate PKC increased ARNA 27 +/- 4% and renal pelvic release of PGE(2) from 500 +/- 59 to 1, 113 +/- 183 pg/min and substance P from 10 +/- 2 to 30 +/- 2 pg/min (all P < 0.01). Indomethacin abolished the increases in substance P release and ARNA. The PDBu-mediated increase in ARNA was also abolished by the substance P-receptor antagonist RP 67580. We conclude that bradykinin contributes to the activation of renal pelvic mechanosensitive neurons by activating PKC. PKC increases ARNA via a PGE(2)-induced release of substance P.